Loading...
Loading...
PTGX| Name | Value |
|---|---|
| Revenues | 4.2M |
| Cost of Revenue | 0.9M |
| Gross Profit | 3.3M |
| Operating Expense | 42.1M |
| Operating I/L | -38.8M |
| Other Income/Expense | 7.5M |
| Interest Income | 7.4M |
| Pretax | -31.3M |
| Income Tax Expense | -0.7M |
| Net Income/Loss | -30.6M |
Protagonist Therapeutics, Inc. is a biopharmaceutical company specializing in peptide-based therapeutic drugs for hematology, blood disorders, and inflammatory diseases. Its leading product, rusfertide (PTG-300), is in Phase II clinical trials for polycythemia vera and hereditary hemochromatosis, with potential applications in other blood disorders. Additionally, the company is developing PN-943, an oral treatment for inflammatory bowel disease, and PN-235, an interleukin-23 receptor antagonist for IBD and non-IBD indications. Protagonist Therapeutics generates revenue through the development and commercialization of these innovative peptide-based drugs, with a focus on addressing unmet medical needs.
